125 related articles for article (PubMed ID: 27875672)
21. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
22. Risk of second breast cancer according to estrogen receptor status and family history.
Bouchardy C; Benhamou S; Fioretta G; Verkooijen HM; Chappuis PO; Neyroud-Caspar I; Castiglione M; Vinh-Hung V; Vlastos G; Rapiti E
Breast Cancer Res Treat; 2011 May; 127(1):233-41. PubMed ID: 20878464
[TBL] [Abstract][Full Text] [Related]
23. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database.
Anderson WF; Chu KC; Chatterjee N; Brawley O; Brinton LA
J Clin Oncol; 2001 Jan; 19(1):18-27. PubMed ID: 11134191
[TBL] [Abstract][Full Text] [Related]
24. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
Mezencev R; Švajdler M
Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
[TBL] [Abstract][Full Text] [Related]
25. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
Jemal A; Ward E; Thun MJ
Breast Cancer Res; 2007; 9(3):R28. PubMed ID: 17477859
[TBL] [Abstract][Full Text] [Related]
26. The development of breast carcinoma in women with thyroid carcinoma.
Chen AY; Levy L; Goepfert H; Brown BW; Spitz MR; Vassilopoulou-Sellin R
Cancer; 2001 Jul; 92(2):225-31. PubMed ID: 11466673
[TBL] [Abstract][Full Text] [Related]
27. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status--the Japan public health center-based prospective study.
Suzuki R; Iwasaki M; Inoue M; Sasazuki S; Sawada N; Yamaji T; Shimazu T; Tsugane S;
Int J Cancer; 2011 Sep; 129(5):1214-24. PubMed ID: 21064092
[TBL] [Abstract][Full Text] [Related]
28. Risk of cancer after use of fertility drugs with in-vitro fertilisation.
Venn A; Watson L; Bruinsma F; Giles G; Healy D
Lancet; 1999 Nov; 354(9190):1586-90. PubMed ID: 10560672
[TBL] [Abstract][Full Text] [Related]
29. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
30. The role of ovarian ablation in the management of breast cancer.
Wirk B
Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
[TBL] [Abstract][Full Text] [Related]
31. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
32. Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor tumor subgroup among Ontario women.
Anderson LN; Cotterchio M; Boucher BA; Kreiger N
Int J Cancer; 2013 Apr; 132(7):1683-92. PubMed ID: 22907507
[TBL] [Abstract][Full Text] [Related]
33. Cancer incidence in a population of Jewish women at risk of ovarian cancer.
Liede A; Karlan BY; Baldwin RL; Platt LD; Kuperstein G; Narod SA
J Clin Oncol; 2002 Mar; 20(6):1570-7. PubMed ID: 11896106
[TBL] [Abstract][Full Text] [Related]
34. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
[TBL] [Abstract][Full Text] [Related]
35. Placental weight and mortality in premenopausal breast cancer by tumor characteristics.
Hajiebrahimi MH; Bahmanyar S; Lambe M; Adolfsson J; Fornander T; Wärnberg F; Cnattingius S
Breast Cancer Res Treat; 2013 Jan; 137(1):297-305. PubMed ID: 23149466
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of women with metachronous breast and ovarian carcinomas.
Liou WS; Hamilton CA; Cheung MK; Osann K; Longacre TA; Teng NN; Husain A; Dirbas FM; Chan JK
Gynecol Oncol; 2006 Oct; 103(1):190-4. PubMed ID: 16569424
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience.
Cortesi L; Turchetti D; Marchi I; Fracca A; Canossi B; Rachele B; Silvia R; Rita PA; Pietro T; Massimo F
BMC Cancer; 2006 Aug; 6():210. PubMed ID: 16916448
[TBL] [Abstract][Full Text] [Related]
38. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.
Dartois L; Fagherazzi G; Baglietto L; Boutron-Ruault MC; Delaloge S; Mesrine S; Clavel-Chapelon F
Int J Cancer; 2016 May; 138(10):2415-27. PubMed ID: 26756677
[TBL] [Abstract][Full Text] [Related]
39. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
40. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
